ESPR - CIK 0001434868
Esperion Therapeutics, Inc. (ESPR) reported revenue of $403.13M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $403.13M | +21.3% |
| FY 2024 | $332.31M | +185.7% |
| FY 2023 | $116.33M | +54.1% |
| FY 2022 | $75.47M | -3.8% |
| FY 2021 | $78.45M | -65.5% |
| FY 2020 | $227.55M | +53.4% |
| FY 2019 | $148.36M | - |
| FY 2018 | $0.00 | - |
Esperion Therapeutics, Inc. (ESPR) reported revenue of $403.13M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Esperion Therapeutics, Inc.'s revenue grew from $0.00 to $403.13M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.